OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
61
Results
Show all
Save search
Copy query
Show results for
Unknown
(46)
Metabolomics
(6)
Genomics
(4)
Proteomics
(3)
Transcriptomics
(2)
Organisms
Alphavirus
(3)
Betaherpesvirinae
(3)
Brassica oleracea var. oleracea
(3)
Cowpox virus
(3)
Coxsackievirus
(3)
Cytomegalovirus
(3)
Dengue virus
(3)
EFO:0001352
(3)
Filoviridae
(3)
Hepatitis B virus
(3)
Human alphaherpesvirus 1
(3)
Human betaherpesvirus 5
(3)
Human immunodeficiency virus
(3)
Human immunodeficiency virus 1
(3)
Human immunodeficiency virus 2
(3)
Influenza A virus
(3)
Influenza C virus
(3)
Japanese encephalitis virus
(3)
Japanese encephalitis virus group
(3)
Lyssavirus rabies
(3)
Monkeypox virus
(3)
Nostoc sp. PCC 7120 = FACHB-418
(3)
Oropouche virus
(3)
Orthopoxvirus
(3)
Orthopoxvirus vaccinia
(3)
Rattus
(3)
Ruditapes decussatus
(3)
Tick-borne encephalitis virus
(3)
Homo sapiens
(1)
Mus musculus
(1)
Organisms
Homo sapiens
(2)
Mus musculus
(1)
Repository
MetaboLights
(6)
ENA
(4)
pride
(3)
geo
(2)
Tissue
Epithelial cell
(2)
Blood cell
(1)
Brain
(1)
Cell culture
(1)
Cell suspension culture
(1)
Disease
Acute myeloid leukemia
(1)
Brain cancer
(1)
Prostate adenocarcinoma
(1)
Technology Type
Mass spectrometry
(3)
Mass spectrometry assay
(3)
Mass Spectrometry
(3)
Data-dependent acquisition
(2)
Affinity proteomics
(1)
Bottom-up proteomics
(1)
Shotgun proteomics
(1)
Instrument Platform
Liquid Chromatography MS - negative - reverse phase
(2)
Liquid Chromatography MS - positive - reverse phase
(2)
Liquid Chromatography MS - negative - hilic
(2)
Liquid Chromatography MS - positive - hilic
(2)
Liquid Chromatography MS - negative - reversed-phase
(1)
Liquid Chromatography MS - positive - reversed-phase
(1)
Liquid Chromatography MS - alternating - reverse-phase
(1)
Metabolite Name
Sapanisertib
(6)
Adenosine
(6)
Creatine
(6)
Doramapimod
(5)
Fludrocortisone acetate
(5)
N6-Succinyl Adenosine
(5)
L-Palmitoylcarnitine
(5)
Jasmonic acid
(5)
Taurocholic acid
(5)
Riboflavin
(5)
L-Serine
(5)
Uridine
(5)
Inosine
(5)
Hypoxanthine
(5)
Ethynodiol diacetate
(4)
Firefly luciferin
(4)
LPE(0:0/18:0)
(4)
Rosiglitazone
(4)
LPE(18:0/0:0)
(4)
7-Ethyl-10-(4-N-aminopentanoic acid)-1-piperidino)carbonyloxycamptothecin
(4)
2-Hydroxyquinoline
(4)
Androsterone sulfate
(4)
Maraviroc
(4)
1,2-Dipalmitoleoyl-sn-glycero-3-phosphocholine
(4)
Capsianoside IV
(4)
[6]-Gingerdiol 3,5-diacetate
(4)
1-Heptadecanoyl-sn-glycero-3-phosphocholine
(4)
9(S),12(S),13(S)-TriHOME
(4)
Quercetin
(4)
Pravastatin
(4)
First Public Date
2026
(1)
2025
(1)
2021
(1)
2018
(1)
Release Date
2022
(9)
2025
(8)
2020
(8)
2024
(7)
2023
(4)
2019
(4)
2021
(3)
2018
(2)
2026
(1)
Lab affiliation
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD.
(1)
Marseille Protéomique, Centre de Recherche en Cancérologie de Marseille, INSERM, CNRS, Institut Paoli-Calmettes, Aix-Marseille University, 13009 Marseille, France
(1)
Systems Pharmacology lab, Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Finland
(1)
Publication date
2026
(6)
2021
(2)
2025
(2)
2024
(1)
Tags
xref:PubMed:35080986
(1)
xref:PubMed:37333134
(1)
xref:PubMed:41406241
(1)
xref:PubMed:42091854
(1)
Previous
page
1 / 7
You're on page
1
page
2
page
3
page
4
page
5
page
6
page
7
Next
page
Sort
by:
Relevance
Page size
10
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
Not available
S-EPMC8994735
|
biostudies-literature
Cite
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
Not available
S-EPMC10113233
|
biostudies-literature
Cite
Establishment and application of a zebrafish model of Werner syndrome identifies sapanisertib as a potential antiaging drug.
Not available
S-EPMC11804616
|
biostudies-literature
Cite
The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple <i>Plasmodium</i> kinases and life cycle stages.
Not available
S-EPMC9951552
|
biostudies-literature
Cite
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
Not available
S-EPMC9365359
|
biostudies-literature
Cite
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
Not available
S-EPMC9732228
|
biostudies-literature
Cite
Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
Not available
S-EPMC7586797
|
biostudies-literature
Cite
A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
Not available
S-EPMC6279485
|
biostudies-literature
Cite
A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
Not available
S-EPMC10726920
|
biostudies-literature
Cite
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Not available
S-EPMC7686313
|
biostudies-literature
Cite
Previous
page
1 / 7
You're on page
1
page
2
page
3
page
4
page
5
page
6
page
7
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
